Newmed Energ Pu AI Stock Analysis
Want to see IL:NWMD full AI Analyst Report?
Newmed Energ Pu (NWMD) AI Stock Analysis
Newmed Energ Pu
(TASE:NWMD)
Newmed Energ Pu's overall score is strongly supported by highly positive earnings momentum, including a 35% production increase and exceptional core operating margins. However, these fundamental strengths are counterbalanced by emerging financial risks, notably a sharp drop in free cash flow and a recent spike in debt levels. Furthermore, a relatively premium valuation and a stock price that remains below its 200-day moving average temper the overall rating.
Newmed Energ Pu (NWMD) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 19.93B
- Dividend Yield
- 3.73%
- Average Volume (3M)
- 1.06M
- Price to Earnings (P/E)
- 23.9
- Beta (1Y)
- 1.09
- Revenue Growth
- -9.32%
- EPS Growth
- -45.02%
- Country
- Israel
- Employees
- 24
- Sector
- Energy
- Sector Strength
- 65
- Industry
- Oil & Gas Exploration & Production
Newmed Energ Pu Business Overview & Revenue Model
Company Description
NewMed Energy - Limited Partnership is an energy firm engaged in the exploration, development, production, and commercialization of petroleum, natural gas, and condensate, primarily operating in Israel and Cyprus. The company holds significant intere...
How the Company Makes Money
Newmed Energy makes money primarily by producing and selling natural gas (and, where applicable, associated hydrocarbons) from its upstream oil & gas interests. Its core revenue model is based on: (1) Sales of produced natural gas under contractual a...
Newmed Energ Pu Earnings Call Summary
The call presented multiple strong operational and financial improvements: production increased ~35%, revenues rose ~53% and net income ~44%, supported by higher gas prices and completed midstream works. Material infrastructure milestones (third pipeline, Ashdod–Ashkelon looping) and progress on major growth projects (Leviathan expansion on schedule, Aphrodite progressing toward FID) provide clear upside. Offsetting considerations include rising operating costs (+$21M), higher finance expenses (+$26M), net debt of ~$1.4B with an upcoming bond maturity in 2027, and some benefits that are timing‑lagged or accrue to partners rather than immediately to NewMed. Overall, positive momentum and meaningful value catalysts outweigh the noted financial and timing challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that Q2‑2026 results included production of 2.7 Bcm (vs. 2.0 Bcm in Q2‑2025, with ~+0.5 Bcm to Egypt), revenues of $293M (vs. $191M), net profit of ~$117–118M, average gas price $6.5/MMBtu (vs. $5.6), and a $60M dividend; net revenues rose ~$86M (≈$59M from higher production, $25M from higher price, $2.1M condensate) partially offset by ~$21M higher costs and ~$26M higher finance expenses, plus $6.8M other revenues and $7.7M discontinued‑operation income. Liquidity/financial guidance: net debt ≈$1.4B, $550M available bank facilities, ~$95M of bond buybacks to date, next bond maturity June‑2027. Capex/project guidance: third pipeline lifts peak capacity to 15.8 Bcm/year (from ~14.5, +1 Bcm), Ashdod–Ashkelon looping adds ~2 Bcm/year (allocated to Leviathan partners), Leviathan Phase‑1b on track for H2‑2029 with total cost ~$2.4B and ~23% complete and a rig to drill 3 wells by year‑end; FAJR+compression due EOY, Nitzana ahead of Phase‑2, Aphrodite FID targeted H1‑2027, and upcoming seismic surveys including a ~5,000‑node OBN survey.
Newmed Energ Pu Financial Statement Overview
Summary
The score reflects exceptional profitability with an 82.9% EBITDA margin and steady historical equity growth. However, this is significantly weighed down by recent net income contraction, a severe drop in free cash flow to $158.5 million, and a spike in total debt pushing leverage above 1.0x.
Income Statement
68PositiveBalance Sheet
65PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 949.33M | 938.07M | 1.14B | 934.60M | 1.14B | 882.50M |
| Gross Profit | 640.92M | 585.08M | 718.10M | 780.70M | 701.70M | 518.10M |
| EBITDA | 787.21M | 760.65M | 874.80M | 782.70M | 872.10M | 657.20M |
| Net Income | 300.36M | 371.29M | 524.60M | 433.60M | 469.70M | 404.90M |
Balance Sheet | ||||||
| Total Assets | 4.66B | 3.97B | 3.99B | 3.85B | 3.94B | 3.85B |
| Cash, Cash Equivalents and Short-Term Investments | 691.82M | 157.53M | 384.50M | 186.70M | 418.30M | 340.85M |
| Total Debt | 2.03B | 1.12B | 1.63B | 1.82B | 2.16B | 2.22B |
| Total Liabilities | 2.68B | 2.08B | 2.21B | 2.33B | 2.65B | 2.91B |
| Stockholders Equity | 1.98B | 1.89B | 1.79B | 1.51B | 1.29B | 938.54M |
Cash Flow | ||||||
| Free Cash Flow | 158.52M | 304.72M | 463.30M | 423.10M | 405.80M | 423.25M |
| Operating Cash Flow | 498.79M | 547.08M | 577.50M | 559.50M | 504.70M | 453.64M |
| Investing Cash Flow | -485.15M | 30.20M | -114.20M | 36.10M | -273.50M | 982.04M |
| Financing Cash Flow | 352.39M | -516.12M | -441.20M | -588.90M | -429.10M | -1.29B |
Newmed Energ Pu Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NWMD, the sentiment is Neutral. The current price of 1695.00 is above the 20-day moving average (MA) of 1670.60, above the 50-day MA of 1646.78, and below the 200-day MA of 1740.66, indicating a neutral trend. The MACD of 29.46 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 60.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:NWMD.
Newmed Energ Pu Peers Comparison
Overall Rating
IL:NWMD65Neutral
IL:DLEKG64Neutral
IL:TMRP63Neutral
IL:TOEN62Neutral
IL:NVPT54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 65Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% |
| 65Neutral | ILS 20.08B | 23.89 | 15.86% | 3.73% | -9.32% | -45.02% | |
| 64Neutral | ILS 14.17B | 4.16 | 35.13% | 5.29% | -37.24% | -73.95% | |
| 63Neutral | ILS 2.08B | 14.72 | ― | 15.86% | -15.98% | -22.66% | |
| 62Neutral | ILS 282.61M | 14.74 | ― | 36.32% | -1.64% | 9.82% | |
| 54Neutral | ILS 14.80B | 14.47 | ― | 3.29% | 920.97% | ― |
* Energy Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:NWMD | Newmed Energy Limited Partnership | 1695.00 | 128.44 | 8.20% | |
| IL:DLEKG | Delek Group | 7780.00 | -490.92 | -5.94% | |
| IL:ISRA | Isramco Negev 2 LP | 220.30 | 10.47 | 4.99% | |
| IL:TOEN | Tomer Energy Royalties (2012) Ltd. | 1380.00 | -378.04 | -21.50% | |
| IL:TMRP | Tamar Petroleum Ltd. | 2570.00 | -618.94 | -19.41% | |
| IL:NVPT | Navitas Petroleum LP | 11990.00 | 507.92 | 4.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
